Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BRII-179

Vaccine · Immune activation, directed at hepatitis B virus surface antigen · developed by Brii Biosciences

Phase 2 Most advanced trial (none active)
2 Registered trials

What is BRII-179?

BRII-179 (VBI-2601) is given by intramuscular injection, sometimes together with interferon alpha, in studies of chronic hepatitis B virus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine
Targets
hepatitis B virus surface antigen (antigen)
Mechanism
Immune activation, directed at hepatitis B virus surface antigen
Therapy area
Gastroenterology, Infectious disease
Developer
Brii Biosciences Limited
In trials of
VIR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06491563 Phase 2 For Treatment of Chronic Hepatitis B Virus Infection Completed VIR
NCT04749368 Phase 2 Hepatitis B, Chronic Completed VIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

For Treatment of Chronic Hepatitis B Virus InfectionHepatitis B, Chronic

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.